Zhejiang Ausun Pharmaceutical 미래 성장
Future 기준 확인 3/6
Zhejiang Ausun Pharmaceutical is forecast to grow earnings and revenue by 20.4% and 17.5% per annum respectively. EPS is expected to grow by 19.8% per annum. Return on equity is forecast to be 13.9% in 3 years.
주요 정보
20.4%
수익 성장률
19.8%
EPS 성장률
| Pharmaceuticals 수익 성장 | 19.3% |
| 매출 성장률 | 17.5% |
| 향후 자기자본 수익률 | 13.9% |
| 애널리스트 커버리지 | Low |
| 마지막 업데이트 | 25 Oct 2024 |
최근 미래 성장 업데이트
업데이트 없음
Recent updates
There's No Escaping Zhejiang Ausun Pharmaceutical Co., Ltd.'s (SHSE:603229) Muted Earnings Despite A 37% Share Price Rise
Oct 08
Improved Earnings Required Before Zhejiang Ausun Pharmaceutical Co., Ltd. (SHSE:603229) Shares Find Their Feet
Jul 31Improved Earnings Required Before Zhejiang Ausun Pharmaceutical Co., Ltd. (SHSE:603229) Stock's 27% Jump Looks Justified
Mar 06수익 및 매출 성장 예측
| 날짜 | 수익 | 수익 | 잉여 현금 흐름 | 작전 현금 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 12/31/2026 | 1,249 | 417 | 378 | 515 | 1 |
| 12/31/2025 | 1,052 | 345 | 215 | 386 | 1 |
| 12/31/2024 | 907 | 293 | 114 | 326 | 1 |
| 9/30/2024 | 835 | 258 | 135 | 295 | N/A |
| 6/30/2024 | 840 | 274 | 52 | 220 | N/A |
| 3/31/2024 | 800 | 250 | 70 | 196 | N/A |
| 12/31/2023 | 817 | 254 | 58 | 222 | N/A |
| 9/30/2023 | 858 | 284 | -66 | 18 | N/A |
| 6/30/2023 | 852 | 273 | 14 | 136 | N/A |
| 3/31/2023 | 822 | 258 | -59 | 168 | N/A |
| 12/31/2022 | 765 | 235 | -151 | 121 | N/A |
| 9/30/2022 | 718 | 213 | -232 | 113 | N/A |
| 6/30/2022 | 665 | 186 | -299 | 41 | N/A |
| 3/31/2022 | 631 | 173 | -156 | 173 | N/A |
| 12/31/2021 | 570 | 146 | -137 | 174 | N/A |
| 9/30/2021 | 537 | 131 | -70 | 221 | N/A |
| 6/30/2021 | 485 | 117 | 5 | 227 | N/A |
| 3/31/2021 | 474 | 110 | -30 | 120 | N/A |
| 12/31/2020 | 409 | 87 | 46 | 138 | N/A |
| 9/30/2020 | 406 | 72 | 55 | 104 | N/A |
| 6/30/2020 | 389 | 78 | 60 | 121 | N/A |
| 3/31/2020 | 329 | 70 | 26 | 80 | N/A |
| 12/31/2019 | 308 | 56 | 38 | 88 | N/A |
| 9/30/2019 | 293 | 62 | 11 | 78 | N/A |
| 6/30/2019 | 257 | 51 | -14 | 43 | N/A |
| 3/31/2019 | 252 | 50 | -38 | 29 | N/A |
| 12/31/2018 | 244 | 44 | -44 | 12 | N/A |
| 9/30/2018 | 255 | 54 | -13 | 46 | N/A |
| 6/30/2018 | 266 | 52 | N/A | 36 | N/A |
| 3/31/2018 | 251 | 43 | N/A | 41 | N/A |
| 12/31/2017 | 240 | 53 | N/A | 49 | N/A |
| 9/30/2017 | 217 | 55 | N/A | 43 | N/A |
| 6/30/2017 | 216 | 62 | N/A | 108 | N/A |
| 3/31/2017 | 197 | 58 | N/A | 114 | N/A |
| 12/31/2016 | 199 | 57 | N/A | 93 | N/A |
| 3/31/2016 | 259 | 62 | N/A | 41 | N/A |
| 12/31/2015 | 263 | 61 | N/A | 54 | N/A |
| 12/31/2014 | 201 | 22 | N/A | 21 | N/A |
| 12/31/2013 | 121 | 16 | N/A | 16 | N/A |
애널리스트 미래 성장 예측
수입 대 저축률: 603229's forecast earnings growth (20.4% per year) is above the savings rate (2.9%).
수익 vs 시장: 603229's earnings (20.4% per year) are forecast to grow slower than the CN market (25.8% per year).
고성장 수익: 603229's earnings are expected to grow significantly over the next 3 years.
수익 대 시장: 603229's revenue (17.5% per year) is forecast to grow faster than the CN market (14% per year).
고성장 수익: 603229's revenue (17.5% per year) is forecast to grow slower than 20% per year.
주당 순이익 성장 예측
미래 자기자본 수익률
미래 ROE: 603229's Return on Equity is forecast to be low in 3 years time (13.9%).